Exploring the capabilities of a versatile, novel, automated closed system for cell and gene therapy manufacturing
New trends and challenges are being identified as more cell and gene therapy institutions move toward clinical trials and into commercialization. Closed manufacturing systems are designed to minimize contamination risks and reduce ISO cleanroom requirements. In combination with digital connectivity, these systems enable repeatable, trackable, and GMP-compliant manufacturing processes.
In this talk, we will discuss the value of moving towards modular, closed-system technologies designed to enable scalable and cost-effective manufacturing, with a highlight of the Gibco CTS Rotea Counterflow Centrifugation System, a revolutionary benchtop, closed system which offers exceptional flexibility for cell washing, concentration, and separation by size, with high cell recovery and throughput rate. The compact footprint, process flexibility, and sterile single-use kit allow the system to seamlessly scale with your process, from research through clinical manufacturing.
Learn more about how the Gibco CTS Rotea Counterflow Centrifugation System’s exceptional versatility enables a broad range of cell processing applications (cell isolation, cell separation by size, small to medium-scale processing, cryopreserved cell wash and media exchange, formulation for cryopreservation, RBC lysis or depletion, viral vector clarification) across a variety of cell types (T cells, NK cells, MSCs, HEK293, iPSC spheroids, PBMC and more) for your cell and gene therapy workflow.
Attendees will update their knowledge of:
- The scalability and flexibility of the latest modular closed-system manufacturing technology applied across a range of cell types as well as viral vectors
- How to improve both throughput and robustness of key steps including: cell isolation, cell separation by size, cryopreserved cell wash and media exchange, formulation for cryopreservation, RBC lysis or depletion, and viral vector clarification
- How to streamline the transition to GMP manufacture in a cost-, time- and space-efficient manner.
Premkumar Jayaraman, PhD
Regional Field Application Scientist, APJ (Cell & Gene Therapy), Thermo Fisher Scientific
Dr. Premkumar Jayaraman currently provides consultation and training for Thermo Fisher Scientific’s cell and gene therapy solutions such as the Gibco Cell Therapy Systems (CTS) brand of products. Prem has over 7 years of expertise in synthetic biology utilizing gene-editing technologies, stem cell bioprocessing (pluripotent and adult stem cells), and viral vector production (lentivirus and adeno-associated viruses). In his previous role as a Research Scientist at the Bioprocessing Technology Institute (A*STAR, Singapore), Prem oversaw a variety of cell and gene therapy projects, from media optimization to upstream process development. Prem received his doctoral degree in Biotechnology from Nanyang Technological University (Singapore).
Scientist III, Field Applications, Thermo Fisher Scientific
Sarah Daoudi is a Field Application Scientist that provides solutions and consultation for Thermo Fisher Scientific’s cell and gene therapy workflows and Gibco Cell Therapy Systems (CTS) brand of products. Sarah has expertise in CAR-T workflows, manufacturing, viral vector production (lentivirus and adeno-associated viruses), and drug development. Formerly a Scientist II at Thermo Fisher Scientific, she helped launch the CTS Rotea System by producing application data, writing and developing new protocols, as well as extensive troubleshooting and customer support. In her previous role as Process Development Research Associate at City of Hope (Duarte, California), Sarah oversaw and worked on improving, troubleshooting, and development of Phase I CAR-T cell therapeutic drugs and workflows for over ten different IRBs. Sarah received her master’s degree in Cell and Molecular Biology from California State University, Fullerton (California).